U.S. Hospitality Stock News

NasdaqCM:AKBA
NasdaqCM:AKBABiotechs

Why Akebia Therapeutics (AKBA) Is Up After Strong Q3 Earnings and Promising Vafseo Kidney Data

In the past week, Akebia Therapeutics reported third-quarter 2025 earnings, showing total revenue rising to US$58.77 million from US$37.43 million a year earlier and a net income swing to US$0.54 million compared to a net loss previously. This robust financial turnaround was accompanied by new clinical data presented at ASN Kidney Week 2025, indicating Vafseo may offer dialysis patients a significantly reduced risk of death or hospitalization versus standard therapy. We’ll explore how this...
NasdaqGM:PUBM
NasdaqGM:PUBMMedia

Why PubMatic (PUBM) Is Up 18.7% After AI-Driven CTV Revenue Surge Outpaces Expectations

PubMatic reported its third-quarter 2025 results last week, showing revenue of US$67.96 million and a net loss of US$6.45 million, both wider than the prior year period, but exceeding adjusted earnings and revenue expectations from analysts. The company spotlighted more than 50% year-over-year Connected TV ad revenue growth and emphasized the impact of its AI-driven innovations, developed with NVIDIA, which have contributed to increased publisher revenues and marketplace...
NYSE:LVWR
NYSE:LVWRAuto

Reassessing LiveWire Group (LVWR) Valuation Following Widened 2025 Loss Guidance and Quarterly Earnings Update

LiveWire Group (LVWR) updated its guidance for 2025, now expecting a wider operating loss range of $72 million to $77 million, up from its previous estimate. This announcement was released together with the company’s third-quarter earnings results and provided key updates for investors. See our latest analysis for LiveWire Group. LiveWire Group’s announcement of a wider expected operating loss for 2025 appears to have weighed on sentiment even as quarterly losses improved from last year. The...
NasdaqCM:ENGN
NasdaqCM:ENGNBiotechs

Could a Shift in enGene (ENGN) Trial Endpoints Reveal New Priorities in Its Clinical Strategy?

enGene Holdings recently reported additional preliminary efficacy data from its pivotal Phase 2 LEGEND trial for detalimogene voraplasmid in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, along with a protocol amendment changing the primary clinical endpoint after discussions with the FDA. This update reveals that earlier patients in the study experienced a lower 12-month complete response rate compared to FDA-approved therapies, leading to significant...